Smith & Nephew plc (LON:SN – Get Free Report) insider Jeremy (Jez) Maiden bought 353 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The shares were acquired at an average price of GBX 1,378 per share, with a total value of £4,864.34.
Smith & Nephew Stock Down 0.1%
Shares of LON SN traded down GBX 2 during trading on Tuesday, reaching GBX 1,383. The company had a trading volume of 2,379,900 shares, compared to its average volume of 343,671. The stock has a market cap of £15.16 billion, a PE ratio of 49.79, a PEG ratio of 0.46 and a beta of 0.62. The business’s 50-day moving average is GBX 1,185.93 and its 200-day moving average is GBX 1,106.25. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on SN. JPMorgan Chase & Co. increased their target price on Smith & Nephew from GBX 1,357 to GBX 1,438 and gave the stock an “overweight” rating in a research note on Wednesday, August 6th. Deutsche Bank Aktiengesellschaft increased their price objective on Smith & Nephew from GBX 1,300 to GBX 1,400 and gave the company a “hold” rating in a research report on Wednesday, August 6th. Finally, Berenberg Bank increased their price objective on Smith & Nephew from GBX 1,100 to GBX 1,300 and gave the company a “hold” rating in a research report on Thursday, August 7th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of GBX 1,379.33.
Smith & Nephew Company Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Read More
- Five stocks we like better than Smith & Nephew
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Tesla Just Had Its Best Day in 2 Months—Here’s What It Means
- How to Calculate Stock Profit
- Retail Roundup: Key Winners and Losers After Q2 Earnings
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Big Analyst Revisions Could Be Ahead for SoFi Stock
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.